Ejtehadi Fardad, Zare Ehsan, Shamsaeefar Alireza, Nikeghbalian Saman, Kazemi Kourosh, Nikoupour Hamed, Eghlimi Hesameddin, Motazedian Nasrin, Moghadami Mohsen, Malekhosseini Seyed Ali
From the Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Exp Clin Transplant. 2021 Aug;19(8):806-810. doi: 10.6002/ect.2020.0443. Epub 2021 Mar 4.
Liver transplant recipients are more susceptible to vancomycin-resistant enterococci colonization than healthy individuals. We investigated the prevalence of vancomycin-resistant enterococci colonization and its effect on the outcomes of liver transplant recipients.
Patients who had undergone primary liver transplant at the Shiraz Organ Transplant Center from 2015 to 2017 were enrolled in this study. Demographic characteristics, laboratory test results, duration of stay in the intensive care unit, total duration of hospital stay, and clinical outcome data were extracted from the Shiraz Organ Transplant Center database. Posttransplant outcomes such as graft rejection, mortality, hospital stay, and kidney function tests were included for the first 90 days after transplant.
A total of 753 liver transplant recipients (470 males and 283 females) were included in this study. Vancomycin-resistant enterococci colonization was identified in 51 patients (6.8%) after transplant at the time of intensive care unit admission. Our study found no significant difference between outcomes for patients with vancomycin-resistant enterococci colonization and outcomes for patients without colonization, including graft rejection, mortality, hospital stay, and kidney function tests.
Our study revealed that asymptomatic vancomycin-resistant enterococci colonization in liver transplant patients has no adverse effect on the duration of posttransplant hospital stay, early mortality rate, graft rejection rate, or kidney function compared with noncolonized patients.
肝移植受者比健康个体更容易发生耐万古霉素肠球菌定植。我们调查了耐万古霉素肠球菌定植的发生率及其对肝移植受者结局的影响。
纳入2015年至2017年在设拉子器官移植中心接受初次肝移植的患者。从设拉子器官移植中心数据库中提取人口统计学特征、实验室检查结果、重症监护病房住院时间、总住院时间和临床结局数据。移植后90天内纳入移植后结局，如移植排斥反应、死亡率、住院时间和肾功能检查。
本研究共纳入753例肝移植受者（男性470例，女性283例）。51例患者（6.8%）在重症监护病房入院时被确定在移植后发生了耐万古霉素肠球菌定植。我们的研究发现，耐万古霉素肠球菌定植患者与未定植患者的结局之间没有显著差异，包括移植排斥反应、死亡率、住院时间和肾功能检查。
我们的研究表明，与未定植患者相比，肝移植患者无症状耐万古霉素肠球菌定植对移植后住院时间、早期死亡率、移植排斥率或肾功能没有不良影响。
